RTTNews | Nov 23, 2021 07:32AM EST

07:32 Tuesday, November 23, 2021 (RTTNews.com) - Aadi Bioscience, Inc. (AADI), a company focused on precision therapies, said on Tuesday that the U.S. Food and Drug Administration or FDA has approved FYARRO, sirolimus protein-bound particles for injectable suspension or albumin-bound to treat locally advanced metastatic malignant perivascular epithelioid cell tumor, known as PEComa.

The company claimed that this is the first and only FDA-approved treatment for advanced malignant PEComa in adults.

FYARRO is intended for intravenous use.

"The approval of FYARRO, the first approved drug for advanced malignant PEComa, an aggressive sarcoma with a poor prognosis and few treatment options, will provide physicians with a new weapon for treating patients with this rare disease," commented Andrew Wagner, a senior oncologist at Dana-Farber Cancer Institute and the Principal Investigator in the pivotal AMPECT registrational trial.

Read the original article on RTTNews ( https://www.rttnews.com/3244373/aadi-gets-fda-approval-for-fyarro-to-treat-advanced-malignant-pecoma.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved